Highlights

• The stock gained over 7% in a single session with notable trading activity.
• Short-term performance outpaced benchmark, while year-to-date returns remain negative.
• Financials reflect continued losses at both standalone and consolidated levels.

Onesource Specialty Pharma Limited (NSE:ONESOURCE) recorded a notable rise on 13 April 2026, closing at ₹1,545.10, up ₹106.20 or 7.38%. The stock traded within a range of ₹1,405.00 to ₹1,554.00, reflecting active participation during the session.

The stock remains below its 52-week high of ₹2,248.00 but above its 52-week low of ₹1,057.00. Annualised volatility stands at 52.92%, indicating significant price fluctuations.

Mixed Performance Across Timeframes

The stock has delivered 12.62% returns over one week and 3.94% over one month, slightly outperforming NIFTY 500 returns of 4.14% and 3.68%, respectively.

However, year-to-date returns remain negative at -13.30%, compared to -7.24% for the benchmark. One-year returns stand at 3.18%, trailing the broader index gain of 6.87%. Long-term return data remains limited.

Trading Activity Shows Higher Delivery

The stock recorded traded volumes of 18.80 lakh shares, translating into a traded value of ₹283.04 crore. Deliverable quantity stood at 44.15%, indicating relatively higher investor participation compared to speculative trades.

The company has a total market capitalisation of ₹17,766.29 crore, with a free float market cap of ₹8,531.92 crore. The impact cost stands at 0.08, suggesting moderate liquidity.

Business Model in Specialty Pharma

Onesource Specialty Pharma Limited operates in the pharmaceutical sector, focusing on specialty products. The company is engaged in developing and manufacturing pharmaceutical solutions, targeting niche and complex therapeutic segments.

Its operations are aligned with specialty and value-added pharmaceutical offerings.

Financial Performance Remains Negative

For the quarter ended December 2025, the company reported standalone total income of ₹29,484.40 lakh with a net loss of ₹6,218.50 lakh and EPS of -5.43.

On a consolidated basis, total income stood at ₹29,496.50 lakh with a net loss of ₹8,869.90 lakh and EPS of -7.74. This indicates continued pressure on profitability.

The stock’s price-to-earnings ratio remains above 50 based on trailing four quarters, reflecting elevated valuation despite negative earnings.

Key Risks

• Continued net losses may impact long-term financial sustainability.
• High volatility increases short-term price risk for market participants.
• Negative returns on a year-to-date basis indicate underlying pressure.
• Pharmaceutical sector regulatory factors may impact operations and approvals.

Summary

Onesource Specialty Pharma has recorded a sharp short-term price increase supported by active trading and relatively higher delivery participation. However, financial performance remains under pressure with continued losses. While short-term momentum is visible, valuation levels, volatility, and profitability challenges remain key factors influencing the stock.

FAQs

1. Why did Onesource Specialty Pharma stock rise recently?
   The stock gained due to short-term momentum, active trading, and increased investor participation.
2. Is Onesource Specialty Pharma profitable?
   No, the company reported net losses in both standalone and consolidated financial results.
3. How does the stock compare with the market?
   It outperformed in the short term but underperformed on a year-to-date basis.